REFERENCES
- Wei J.T., Calhoun E., Jacobsen S.J. Urologic diseases in America project: Benign prostatic hyperplasia. J. Urol. 2005; 173: 1256–1261
- Salva P., Bianchetti G., Morselli P, Garcia-Teresa G., Costa J. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses. Biopharm. Drug Disp. 1992; 13: 583–590
- http://www.drugs.com/pdr/alfuzosin_hydrochloride.html, PDR Drug information for hydrochloride
- http://www.uspharmacist.com/oldformat.asp?url=ce/2947/default.htm, US pharmacist new drug review
- Gil E.C., Colarte A.J., Bataille B., Pedraz J.L., Rodriguez F., Heinamaki J. Development and optimization of a novel sustained release dextran tablet formulation for Propranolol hydrochloride. Int. J. Pharm. 2006; 317: 32–39
- Kuksal A., Tiwary A.K., Jain N.K., Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of Zidovudine: Influence of combination of hydrophilic and hydrophobic matrix former. AAPS Pharm. Sci. Tech. 2006; 7: E1–E9
- Li F.Q., Hu J.H., Deng J.X., Su H., Xu S., Liu J.Y. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int. J. Pharm. 2006; 324: 152–157
- Keith M. L. Lachman, H. A. Liberman, J. L. KanigCompression and consolidation of the powdered solids. Theory and Practice of Industrial Pharmacy3rd, . Varghese Publishing House, MumbaiIndia 1991; 66–72
- Rouchouse A., Manoha M., Durand A., Thenot J. P. Direct high-performance liquid chromatographic determination of the entainomers of alfuzosin in plasma on a second generation alpha 1-acid glycoprotein chiral stationary phases. J. Chromatogr. 1990; 506: 601–610
- 10. USP XXIV, 17th Ed., Rockville, 1947, MD 2000.
- Hayashi T., Kanbe H., Okada M., Suzuki M., Ikeda Y., Onuki Y., Kaneko T., Sonobe T. Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int. J. Pharm. 2005; 304: 91–101
- Reza M.S., Quadir M.A., Haider S.S. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J. Pharm. Pharm. Sci. 2003; 6: 282–91
- Yan G., Li H., Zhang R, Ding D. Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets. Drug Dev. Ind. Pharm. 2000; 26: 681–686
- Takka S., Singh B.S., Sakr A. Influence of methacrylic acid and hydroxypropylmethyl cellulose on the tablet properties and in vitro release of dextromethorphan hydrobromide. Pharmazie 2003; 58: 886–890
- Lee B.J., Ryu S.G., Cui J.H. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev. Ind. Pharm. 1999; 25: 493–501
- Scheer M. tablets and synthesis. US Patent US2006/0062845 A1, March 23, 2006
- Tabandeh H., Mortazavi S.A., Guilani T.B. Preparation of sustained release matrix tablets of aspirin with ethyl cellulose, Eudragit RS 100 and Eudragit S 100 and studying the release profiles and their sensitivity of tablet hardness. Iranian J. Pharm. Res. 2003; 201–206
- Boza A., Caraballo I., Alvarez-Fuentes J, Rabasco A.M. Evaluation of Eudragit® RS-PO and Ethocel® 100 matrices for the controlled release of lobenzarit disodium. Drug Dev. Ind. Pharm. 1999; 25: 229–233